Oral · GLP-1 agonist
CT-996 / RO7795081
6 trials in this molecule. Source: ClinicalTrials.gov, as of July 6, 2026.
Trials
6
Ongoing
4
Recruiting
2
Completed
2
Sites
72
Countries
8
Endpoints
76
Composite endpoints
1
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Where the program stands
Trials by phase
Phase 1
4
Phase 2
2
Trials by status
Recruiting
2
Active, not recruiting
2
Completed
2
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Safety / tolerability / PK
58
Weight & body composition
11
Glycemic / diabetes
4
Patient-reported / QoL
1
Other clinical outcomes
1
Other (unclassified)
1
Top 20 metrics across this asset's endpoints
HbA1c, changeGlycemic
2
HbA1c <5.7% achievementGlycemic
1
Fasting glucose, changeGlycemic
1
Body weight, % changeWeight
1
Body weight, absolute change (kg)Weight
1
≥15% weight-loss respondersWeight
1
Treatment-emergent AEs (any)Safety/PK
1
Documented hypoglycemiaSafety/PK
1
Plasma concentration (steady state)Safety/PK
1
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
6 of 6
Showing 1-6 of 6 trials